843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma

Sato, T., Ikeguchi, A. P., Nathan, P., Carvajal, R. D., Shoushtari, A. N., Gajewski, T. F., Hassel, J. C., Rioth, M., Leyvraz, S., Daniels, G. A., Hernandez-Aya, L., Johnson, D. B., Kim, K., Piulats Rodriguez, J. M., Cowey, C. L., Lockwood, S., Collins, L., Karakuzu, O., Sacco, J. J., & Butler, M. O. (2022). 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma. Annals of Oncology, 33, S934–S935. https://doi.org/10.1016/j.annonc.2022.07.969
Authors:
T. Sato
A.P. Ikeguchi
P. Nathan
R.D. Carvajal
A.N. Shoushtari
T.F. Gajewski
J.C. Hassel
M. Rioth
S. Leyvraz
G.A. Daniels
L. Hernandez-Aya
D.B. Johnson
K. Kim
J.M. Piulats Rodriguez
C.L. Cowey
S. Lockwood
L. Collins
O. Karakuzu
J.J. Sacco
M.O. Butler
Affiliated Authors:
R.D. Carvajal
Columbia Affiliation:
Subjects:
Ocular Cancer Research and Treatment (OpenAlex Topic)
Nanotechnology and Imaging for Cancer Therapy and Diagnosis (OpenAlex Topic)
Targeted Protein Degradation in Biomedical Research (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2022.07.969
DOI:
10.1016/j.annonc.2022.07.969
Journal:
Annals of Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: